Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 3/20 | 0.46 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.37 |
| ▸ | KDM1A | O60341 | 2/20 | 0.36 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.35 |
| ▸ | FLT3 | P36888 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | DAO | P14920 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5362383 | 0.92 | NR3C1 (0.40) | NR3C1KDM1AHRH4FLT3KDM4E | |
| SCHEMBL5358723 | 0.83 | MEN1 (0.42) | AKR1B1HRH4FLT3KDM4EMAPT | |
| SCHEMBL4311651 | 0.75 | HRH4 (0.43) | NR3C1HRH4 | |
| SCHEMBL6316631 | 0.72 | PGR (0.47) | AKR1B1KDM1A | |
| SCHEMBL12948668 | 0.71 | FLT3 (0.41) | HRH4FLT3KDM4EMAPTDAO | |
| SCHEMBL3062818 | 0.71 | FLT3 (0.44) | HRH4FLT3KDM4EMAPTDAO | |
| SCHEMBL779503 | 0.70 | ADRA2A (0.46) | AKR1B1KDM1A | |
| SCHEMBL9906167 | 0.67 | KDM1A (0.49) | KDM1A | |
| SCHEMBL4133169 | 0.67 | CYP3A4 (0.58) | AKR1B1KDM1A | |
| SCHEMBL7072344 | 0.67 | SLC18A3 (0.43) | AKR1B1KDM1AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050107458-A1 | Isomeric fused pyrrolocarbazoles and isoindolones | CEPHALON, INC. (US) | 2005-05-19 | — | — | US | disclosed |
| US-6872746-B2 | Isomeric fused pyrrolocarbazoles and isoindolones | CEPHALON, INC. (US) | 2005-03-29 | — | — | US | disclosed |
| EP-1206473-B1 | ISOMERIC FUSED PYRROLOCARBAZOLES AND ISOINDOLONES | CEPHALON INC (US) | 2004-10-20 | — | — | EP | disclosed |
| US-20030216419-A1 | Isomeric fused pyrrolocarbazoles and isoindolones | CEPHALON, INC. | 2003-11-20 | — | — | US | disclosed |
| US-6635669-B2 | Kinase inhibitor; benign prostatic hyperplasia | CEPHALON, INC. | 2003-10-21 | — | — | US | disclosed |
| US-20020147341-A1 | Isomeric fused pyrrolocarbazoles and isoindolones | CEPHALON, INC. | 2002-10-10 | — | — | US | disclosed |
| US-6399780-B1 | KINASE INHIBITORS; ANTICANCER AGENTS | CEPHALON, INC. | 2002-06-04 | — | — | US | disclosed |
| EP-1206473-A1 | ISOMERIC FUSED PYRROLOCARBAZOLES AND ISOINDOLONES | CEPHALON, INC. (US) | 2002-05-22 | — | — | EP | disclosed |
| WO-2001014380-A1 | ISOMERIC FUSED PYRROLOCARBAZOLES AND ISOINDOLONES | CEPHALON, INC. (US) | 2001-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030216419-A1 | Isomeric fused pyrrolocarbazoles and isoindolones | PIN1, QPCT, PAICS | NR3C1 4102/4885AKR1B1 644/4885KDM1A 4229/4885 |
| US-20020147341-A1 | Isomeric fused pyrrolocarbazoles and isoindolones | PIN1, QPCT, PAICS | NR3C1 4102/4885AKR1B1 644/4885KDM1A 4229/4885 |
| US-20050107458-A1 | Isomeric fused pyrrolocarbazoles and isoindolones | PIN1, QPCT, PAICS | NR3C1 4102/4885AKR1B1 644/4885KDM1A 4229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.